The Age-Specific Quantitative Effects of Metabolic Risk Factors on Cardiovascular Diseases and Diabetes: A Pooled Analysis
Open accessThe DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effects of systolic blood pressure (SBP), serum total cholesterol (TC), fasting plasma glucose (FPG), and body mass index (BMI) on the risk of cardiovascular diseases (CVD) have been established in epidemiological studies, but consistent estimates of effect sizes by age and sex are not available. METHODS: We reviewed large cohort pooling projects, evaluating effects of baseline or usual exposure to metabolic risks on ischemic heart disease (IHD), hypertensive heart disease (HHD), stroke, diabetes, and, as relevant selected other CVDs, after adjusting for important confounders. We pooled all data to estimate relative risks (RRs) for each risk factor and examined effect modification by age or other factors, using random effects models. RESULTS: Across all risk factors, an average of 123 cohorts provided data on 1.4 million individuals and 52,000 CVD events. Each metabolic risk factor was robustly related to CVD. At the baseline age of 55-64 years, the RR for 10 mmHg higher SBP was largest for HHD (2.16; 95% CI 2.09-2.24), followed by effects on both stroke subtypes (1.66; 1.39-1.98 for hemorrhagic stroke and 1.63; 1.57-1.69 for ischemic stroke). In the same age group, RRs for 1 mmol/L higher TC were 1.44 (1.29-1.61) for IHD and 1.20 (1.15-1.25) for ischemic stroke. The RRs for 5 kg/m(2) higher BMI for ages 55-64 ranged from 2.32 (2.04-2.63) for diabetes, to 1.44 (1.40-1.48) for IHD. For 1 mmol/L higher FPG, RRs in this age group were 1.18 (1.08-1.29) for IHD and 1.14 (1.01-1.29) for total stroke. For all risk factors, proportional effects declined with age, were generally consistent by sex, and differed by region in only a few age groups for certain risk factor-disease pairs. CONCLUSION: Our results provide robust, comparable and precise estimates of the effects of major metabolic risk factors on CVD and diabetes by age group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and the risk of CVD increases continuously with rising fasting plasma glucose levels, even before reaching levels sufficient for a diabetes diagnosis [5].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Self-citation(2002) · The Lancet · doi:10.1016/s0140-6736(02)11911-8 · Cited by 10,266
Self-citationTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · cited 1×
“For BMI and FPG, confounding remains a concern as evidence from randomized trials of disease outcomes is either very limited for practical reasons (BMI) or provides mixed results (FPG) [49–52].”
BackgroundBariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800 · cited 14×
“Metabolic risk factors We compared and pooled RRs for the effects of key metabolic risk factors: SBP, TC, FPG, and adiposity measured by BMI, from major global pooling projects.”
BackgroundInfluentialCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050 · cited 1×
“Recent analyses of national and regional trends in exposure to CVD risk factors have shown considerable worldwide increases in BMI [26] and blood glucose [24], concurrent with increases in SBP and TC in some regions [23,25].”
BackgroundSelf-citationGupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Selected major risk factors and global and regional burden of disease
Ezzati, M., Lopez, A. D., Rodgers, A., Vander Hoorn, S., & Murray, C. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11403-6 · Cited by 3,594
Self-citationDanaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Cowan, M. J., Paciorek, C. J., Lin, J. K., Farzadfar, F., Khang, Y.-H., Stevens, G. A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60679-x · Cited by 3,568 · cited 1×
“Recent analyses of national and regional trends in exposure to CVD risk factors have shown considerable worldwide increases in BMI [26] and blood glucose [24], concurrent with increases in SBP and TC in some regions [23,25].”
BackgroundSelf-citationEzzati, M., López, A. D., Rodgers, A., & Murray, C. J. L. (2004) · Cited by 3,319
Self-citationDanaei, G., Ding, E. L., Mozaffarian, D., Taylor, B., Rehm, J., Murray, C. J. L., & Ezzati, M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000058 · Cited by 2,860 · cited 1×
“The theoretical minimum-risk exposure distribution (TMRED) is an alternative exposure distribution that aims to measure the effects of all non-optimal levels of exposure in a comparable way across risk factors [2,3,35,36].”
BackgroundSelf-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775 · cited 3×
“More recent evidence from randomized trials of antihypertensive drugs suggests that benefits of lowering blood pressure may continue to 110 mmHg or lower [32]; the lowest observed levels in the Figure 1.”
BackgroundMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Global Burden of Disease and Risk Factors
(2006) · World Bank, Washington, DC eBooks · doi:10.1596/978-0-8213-6262-4 · Cited by 2,605
Self-citationBody-mass index and mortality among 1.46 million white adults
Berrington de Gonzalez, A., Hartge, P., Cerhan, J. R., Flint, A. J., Hannan, L., MacInnis, R. J., Moore, S. C., Tobias, G. S., Anton-Culver, H., Freeman, L. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000367 · Cited by 2,317
Bariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656
Reeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. (2007) · BMJ · doi:10.1136/bmj.39367.495995.ae · Cited by 1,507 · cited 1×
“Evidence from a large prospective study with multiple measurements of weight and height showed that regression dilution bias did not substantially affect the RRs for BMI, reflecting its relative stability compared with the other metabolic risk factors [30].”
ResultRay, K. K., Seshasai, S. R. K., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., & Sattar, N. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60697-8 · Cited by 1,383 · cited 1×
“In particular, a meta-analysis of the 4 largest randomized trials concluded that more intensive glucose lowering causes a ‘‘modest but significant cardiovascular benefit in the short to medium term’’ [57].”
BackgroundDanaei, G., Finucane, M. M., Lin, J. K., Singh, G. M., Paciorek, C. J., Cowan, M. J., Farzadfar, F., Stevens, G. A., Lim, S. S., Riley, L. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62036-3 · Cited by 1,239 · cited 1×
“Recent analyses of national and regional trends in exposure to CVD risk factors have shown considerable worldwide increases in BMI [26] and blood glucose [24], concurrent with increases in SBP and TC in some regions [23,25].”
BackgroundSelf-citationThe Emerging Risk Factors Collaboration (2011) · The Lancet · doi:10.1016/s0140-6736(11)60105-0 · Cited by 1,216
Law, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210 · cited 1×
“This is less of a concern for SBP and TC where there is overwhelming evidence from randomized trials of antihypertensives and cholesterol-lowering drugs that corroborate the evidence from observational studies on causal effects and their magnitude [8,31,32].”
BackgroundIntensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189 · cited 1×
“Several meta-analyses of randomized trials of intensive versus moderate glucose lowering in diabetic patients have shown significant reduction in the risk of myocardial infarction and other major cardiovascular events [56–58].”
BackgroundSelf-citationComparative quantification of health risks conceptual framework and methodological issues
Murray, C. J., Ezzati, M., Lopez, A. D., Rodgers, A., & Vander Hoorn, S. (2003) · Population Health Metrics · doi:10.1186/1478-7954-1-1 · Cited by 887 · cited 2×
“The theoretical minimum-risk exposure distribution (TMRED) is an alternative exposure distribution that aims to measure the effects of all non-optimal levels of exposure in a comparable way across risk factors [2,3,35,36].”
BackgroundSelf-citationAssociation between body-mass index and risk of death in more than 1 million Asians
Zheng, W., McLerran, D. F., Rolland, B., Zhang, X., Inoue, M., Matsuo, K., He, J., Gupta, P. C., Ramadas, K., Tsugane, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010679 · Cited by 885 · cited 2×
“We did not use the National Cancer Institute (NCI) Cohort Consortium [14] and a recent pooled analysis of Asian cohorts [15] for BMI effect sizes because these studies reported RRs for cardiovascular diseases (CVD) combined but not separately for ischemic heart disease (IHD) and stroke.”
BackgroundMethodSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803 · cited 1×
“Several meta-analyses of randomized trials of intensive versus moderate glucose lowering in diabetic patients have shown significant reduction in the risk of myocardial infarction and other major cardiovascular events [56–58].”
BackgroundSjöström, C. D., Lissner, L., Wedel, H., & Sjöström, L. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00436.x · Cited by 693 · cited 14×
“Metabolic risk factors We compared and pooled RRs for the effects of key metabolic risk factors: SBP, TC, FPG, and adiposity measured by BMI, from major global pooling projects.”
BackgroundInfluentialBlood pressure and cardiovascular disease in the Asia Pacific region
(2003) · Journal of Hypertension · doi:10.1097/00004872-200304000-00013 · Cited by 644 · cited 4×
“Effect estimates in prior global comparative risk assessment (CRA) analyses of metabolic risk factors including systolic blood pressure (SBP), serum total cholesterol (TC), fasting plasma glucose (FPG), and body mass index (BMI) were based on the Asia Pacific Cohort Studies Collaboration (APCSC) and selected other coh…”
MethodInfluentialChen, Z., Peto, R., Collins, R., MacMahon, S., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537 · cited 13×
“For these reasons, and considering the overwhelming evidence from observational studies of the graded increase in risk of CVD with higher blood glucose levels, we included IHD and stroke as outcomes of high blood glucose.”
BackgroundInfluentialFarzadfar, F., Finucane, M. M., Danaei, G., Pelizzari, P. M., Cowan, M. J., Paciorek, C. J., Singh, G. M., Lin, J. K., Stevens, G. A., Riley, L. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62038-7 · Cited by 513 · cited 1×
“Recent analyses of national and regional trends in exposure to CVD risk factors have shown considerable worldwide increases in BMI [26] and blood glucose [24], concurrent with increases in SBP and TC in some regions [23,25].”
BackgroundSelf-citationSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.008 · Cited by 471
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435 · cited 1×
“Another issue is that some trials have been of short duration, perhaps too short to have observed an effect [60].”
BackgroundDanaei, G., Lawes, C. M., Vander Hoorn, S., Murray, C. J., & Ezzati, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69700-6 · Cited by 414 · cited 1×
“Effect estimates in prior global comparative risk assessment (CRA) analyses of metabolic risk factors including systolic blood pressure (SBP), serum total cholesterol (TC), fasting plasma glucose (FPG), and body mass index (BMI) were based on the Asia Pacific Cohort Studies Collaboration (APCSC) and selected other coh…”
MethodSelf-citationMeta-analysis of randomised controlled trials
Kelly, C. P. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63834-2 · Cited by 382
Cholesterol, coronary heart disease, and stroke in the Asia Pacific region.
Asia Pacific Cohort Studies Collaboration (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg106 · Cited by 382 · cited 14×
“For these reasons, and considering the overwhelming evidence from observational studies of the graded increase in risk of CVD with higher blood glucose levels, we included IHD and stroke as outcomes of high blood glucose.”
BackgroundInfluentialAsia Pacific Cohort Studies Collaboration (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh163 · Cited by 375 · cited 1×
“suggested by APCSC for IHD and diabetes [13].”
MethodSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191305 · Cited by 348
Assessing possible hazards of reducing serum cholesterol
Law, M. R., Thompson, S. G., & Wald, N. J. (1994) · BMJ · doi:10.1136/bmj.308.6925.373 · Cited by 309 · cited 1×
“There may also be an increased risk of haemorrhagic stroke at low cholesterol levels [11],[44,45].”
BackgroundBlood glucose and risk of cardiovascular disease in the Asia Pacific region.
Asia Pacific Cohort Studies Collaboration (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2836 · Cited by 302 · cited 4×
“Effect estimates in prior global comparative risk assessment (CRA) analyses of metabolic risk factors including systolic blood pressure (SBP), serum total cholesterol (TC), fasting plasma glucose (FPG), and body mass index (BMI) were based on the Asia Pacific Cohort Studies Collaboration (APCSC) and selected other coh…”
MethodInfluentialFarzadfar, F., Murray, C. J., Gakidou, E., Bossert, T., Namdaritabar, H., Alikhani, S., Moradi, G., Delavari, A., Jamshidi, H., & Ezzati, M. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61349-4 · Cited by 231
Self-citationMechanisms of plaque stabilization with statins
Libby, P., & Aikawa, M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03267-8 · Cited by 229 · cited 1×
“, atheromatous plaque stabilization anti-inflammatory effects, or inhibition of platelet aggregation [41].”
BackgroundThe Emerging Risk Factors Collaboration (2007) · European Journal of Epidemiology · doi:10.1007/s10654-007-9165-7 · Cited by 188
Reaven, P. D., Moritz, T. E., Schwenke, D. C., Anderson, R. J., Criqui, M., Detrano, R., Emanuele, N., Kayshap, M., Marks, J., Mudaliar, S., et al. (2009) · Diabetes · doi:10.2337/db09-0618 · Cited by 182 · cited 1×
“For BMI and FPG, confounding remains a concern as evidence from randomized trials of disease outcomes is either very limited for practical reasons (BMI) or provides mixed results (FPG) [49–52].”
BackgroundThe Asia Pacific Cohort Studies Collaboration
Woodward, M., & Martiniuk, A. L. C. (2003) · Cited by 127
Self-citationThompson, S., Kaptoge, S., White, I., Wood, A., Perry, P., & Danesh, J. (2010) · International Journal of Epidemiology · doi:10.1093/ije/dyq063 · Cited by 112 · cited 1×
“The sources used were the Asia Pacific Cohort Studies Collaboration (APCSC), the Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe (DECODE), the Emerging Risk Factor Collaboration (ERFC) and the Prospective Studies Collaboration (PSC) [9–13,16–22,27–29].”
MethodSelf-citationRise of blood pressure with age. New evidence of population differences.
Rodriguez, B. L., Labarthe, D. R., Huang, B., & Lopez-Gomez, J. (1994) · Hypertension · doi:10.1161/01.hyp.24.6.779 · Cited by 104
Singh, G. M., Danaei, G., Pelizzari, P. M., Lin, J. K., Cowan, M. J., Stevens, G. A., Farzadfar, F., Khang, Y.-H., Lu, Y., Riley, L. M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.058834 · Cited by 93
Self-citationCohort profile: the Asia Pacific Cohort Studies Collaboration
Woodward, M., Barzi, F., Martiniuk, A., Fang, X., Gu, D., Imai, Y., Lam, T., Pan, W., Rodgers, A., Suh, I., et al. (2006) · International Journal of Epidemiology · doi:10.1093/ije/dyl222 · Cited by 86 · cited 3×
“Effect estimates in prior global comparative risk assessment (CRA) analyses of metabolic risk factors including systolic blood pressure (SBP), serum total cholesterol (TC), fasting plasma glucose (FPG), and body mass index (BMI) were based on the Asia Pacific Cohort Studies Collaboration (APCSC) and selected other coh…”
MethodSelf-citationThe DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe.
Balkau, B. (2000) · PubMed · Cited by 79
Murray, C. J. L., Kulkarni, S. C., & Ezzati, M. (2006) · Circulation · doi:10.1161/circulationaha.105.595777 · Cited by 62
Self-citationThe Intersalt Study: Main Results, Conclusions and Some Implications
Elliott, P., Marmot, M. G., Dyer, A. R., Joossens, J. V., Kesteloot, H., Stamier, R., Stamler, J. F., & Rose, G. (1989) · Clinical and Experimental Hypertension · doi:10.3109/10641968909035389 · Cited by 48 · cited 1×
“populations included in the Intersalt study were below 100 mmHg [42].”
Background(1999) · European Journal of Cardiovascular Risk · doi:10.1177/204748739900600508 · Cited by 23
Ezzati, M. (2008) · Elsevier eBooks · doi:10.1016/b978-012373960-5.00331-2 · Cited by 17
Self-citationEngels, E. (2000) · doi:10.1002/1097-0258(20000715)19:13 · Cited by 2
Research works printed but not linked: 2
- James WPT, Jackson-Leach R, Ni Mhurchu C, Kalamara E, Shayeghi M, <etal>et al</etal>.. (2004) Overweight and obesity (high body mass index). In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks. Geneva: World Health Organization. pp. 497–596.
- Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, <etal>et al</etal>.. (2004) High Blood Pressure. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks. Geneva: World Health Organization. pp. 497–596.
Cited by
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Self-citationHeart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Forouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Self-citationHeart disease and stroke statistics-2018 update: a report from the american heart association
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., Chiuve, S. E., Cushman, M., Delling, F. N., Deo, R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000558 · Cited by 7,146
Metadata
- Authors
- Singh, G. M., Danaei, G., Farzadfar, F., Stevens, G. A., Woodward, M., Wormser, D., Kaptoge, S., Whitlock, G., Qiao, Q., Lewington, S., Di Angelantonio, E., vander Hoorn, S., Lawes, C. M. M., Ali, M. K., Mozaffarian, D., Ezzati, M., Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group; Asia-Pacific Cohort Studies Collaboration (APCSC), (DECODE), D. E. C. A. O. D. C. I. E., Emerging Risk Factor Collaboration (ERFC), & Prospective Studies Collaboration (PSC)
- Affiliations
- Harvard University (US)
- Tehran University of Medical Sciences (IR)
- World Health Organization (CH)
- The University of Sydney (AU)
- University of Cambridge (GB)
- University of Oxford (GB)
- University of Helsinki (FI)
- University of Auckland (NZ)
- Emory University (US)
- Brigham and Women's Hospital (US)
- MRC Centre for Environment and Health (GB)
- Corresponding author
- Ezzati, Majid
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-07-30
- Volume
- 8
- Issue
- 7
- Pages
- e65174
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3728292
- OpenAlex
- W2122520859
- Cited by
- 772
- References
- 67
- Citations by year
- 2026: 29 · 2025: 64 · 2024: 84 · 2023: 87 · 2022: 103 · 2021: 86 · 2020: 85 · 2019: 66 · 2018: 43 · 2017: 49 · 2016: 41 · 2015: 18 · 2014: 16 · 2013: 1
- FWCI
- 19.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- Pure Amsterdam UMC (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Monash University Research Portal (Monash University) (acceptedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Työväentutkimus Vuosikirja (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Site cant be reached (submittedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- World Health Organization
- National Institute for Health and Care Research (NF-SI-0512-10165)
- British Heart Foundation (RG/08/013/25942, RG/07/008/23674, RG/08/014/24067)
- Imperial College London
- Imperial College Healthcare NHS Trust
- Medical Research Council (MR/K005901/1, MR/L003120/1)
- Economic and Social Research Council (ES/F02679X/1)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK007703., T32DK007703)
- National Institute of Environmental Health Sciences (P30ES005605)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- metabolic risk factors, cardiovascular disease, diabetes mellitus, systolic blood pressure, total cholesterol, fasting blood glucose, body mass index, ischemic heart disease, hypertensive heart disease, stroke, sex differences, pooled cohort analysis, relative risk, effect modification by age
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Female, Humans, Male, Middle Aged, Risk, Sex Factors, Body Mass Index, Patient Outcome Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.